Business Wire

VA-HILTON

27.1.2020 15:35:09 CET | Business Wire | Press release

Share
Hilton Delivers Record-Breaking Growth and Positive Impact in 100th Year of Hospitality

Hilton (NYSE: HLT) announced that its centennial year featured record-breaking growth, awards for its inclusive workplace culture, and continued recognition of positive community impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005397/en/

“Throughout the last 100 years, Hilton has had a tremendous positive impact on billions of lives across the globe,” said Christopher J. Nassetta, president & chief executive officer, Hilton. “As we look toward the future, we will continue to prioritize sustainable and inclusive growth, enabling us to further strengthen the collective impact we have on the people and communities we serve.”

In 2019, Hilton achieved 6.6 percent net unit growth by adding nearly 470 hotels and reaching 6,110 properties globally with more than 971,000 rooms in 119 countries and territories. The company also grew its development pipeline to more than 387,000 rooms across 15 of its brands, supported by more than 116,000 rooms approved in 72 countries and territories. In addition, Hilton achieved a new construction start record of nearly 87,000 rooms.

“Hilton’s growth and performance are a testament to our resilient business model,” said Kevin Jacobs, chief financial officer, Hilton. “In addition to our record-breaking growth across approvals, construction starts and net units, we are delivering on our commitment to serve any guest, anywhere in the world, for any travel need.”

Record Growth: Effect on Economies

Travel with Purpose: Effect on Communities

  • Launched The Hilton Effect Foundation , dedicated to creating a better world to travel
  • Named the global industry leader in sustainability on the Dow Jones Sustainability Indices (DJSI), the most prestigious ranking for corporate responsibility
  • Recognized as the only hospitality company on Fortune’s Change the World list for the second year in a row
  • Named to climate change “A-List” by the environmental impact nonprofit CDP
  • Expanded decade-long soap recycling program , already the largest in the hospitality industry, to more than 5,300 properties in 70 countries and territories
  • Exceeded Open Doors pledge to connect, prepare or employ one million young people by 2019
  • Invested in local communities by contributing nearly 550,000 volunteering hours at nearly 10,500 events and expanding food donation initiative to all Hilton managed hotels in the U.S. and Canada

Customer Innovations: Effect on Guests

  • Welcomed 178 million guests at its properties worldwide and the 100 millionth Hilton Honors member , growing the award-winning loyalty program by 21 percent to more than 103 million members at year-end
  • Launched a first-of-its-kind travel and hospitality partnership with Lyft , allowing Hilton Honors members to earn and redeem Hilton Honors Points when they ride with Lyft
  • Achieved record numbers of package redemptions through the Hilton Honors Experiences Platform , and hosted intimate music events via an expanded partnership with Live Nation , the world’s leading live entertainment company
  • Partnered with iHeartRadio to allow guests to stream live radio stations, thousands of music playlists and podcasts directly from their TVs through Hilton’s high-tech Connected Room guest technology platform
  • Became the first hospitality company to participate in research aboard the International Space Station , when the DoubleTree chocolate chip cookie became the first food baked in space inside a prototype oven as part of a landmark microgravity experiment

World’s Best Workplace: Effect on Team Members

  • Named #1 Best Company to Work for in the U.S. by Fortune magazine and Great Place to Work®
  • Ranked #2 World’s Best Workplace , appearing on Fortune magazine and Great Place to Work’s® annual list of the 25 World’s Best Workplaces for the fourth consecutive year
  • Recognized by Great Place to Work® in 17 countries and 3 regions including: Argentina #1, Italy #1, Peru #1, Saudi Arabia #1, Turkey #1, United States #1, China #2, Asia #3, United Arab Emirates #3, United Kingdom #3, Australia #3, Mexico #4, Colombia #4, Netherlands #7, Europe #10, Latin America #11, Germany #12, Brazil #14, India #16, Canada #29
  • Named #1 workplace in the U.S. for Parents and Women ; #2 workplace for Millennials by Great Place to Work® and Fortune magazine
  • Named #4 Top 50 Company for Diversity by DiversityInc and received a perfect score on the Human Rights Campaign Corporate Equality Index for the seventh consecutive year
  • Celebrated 100th anniversary with more than 420,000 Team Members** and created more than 25,000 new jobs worldwide***
  • Achieved Operation: Opportunity five-year target of hiring 30,000 veterans, military spouses and caregivers, and expanded military-friendly commitment by pledging to make 25,000 additional hires by 2025, while also enhancing training and development opportunities
  • Expanded family-friendly benefits including an extension to parental leave and an industry-first partnership with Milk Stork to enable Team Members to easily ship or carry breast milk home to their babies while traveling for work

To learn more about Hilton, please visit newsroom.hilton.com .

*Industry data from STR
** Corporate, owned, managed and franchised employees globally
***As a result of opening properties across Hilton’s portfolio

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,100 properties with more than 971,000 rooms, in 119 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. Through the award-winning guest loyalty program Hilton Honors, more than 103 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye